Notably, combination treatment with Twist1 siRNA LNP and Egfrviii CAR T cells substantially extended animal survival (+8.5 days, P < 0.0001; Fig. 5G) and delayed tumor growth (Fig. 5H, left), showing comparable therapeutic efficacy to combination therapy with harmine and CAR T cells. The gene discussed is TWIST1; the disease is neoplasm.